Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.68
$0.13(0.89%)
At close: 4:00 PM EDT
$14.68
$0.13(0.89%)
Day’s Range― - ―
52-Week Range$9.22 - $19.60
Previous CloseN/A
Volume268.93K
Average Volume (3M)119.15K
Market Cap
$438.32M
Enterprise Value$560.15M
Total Cash (Recent Filing)$51.70M
Total Debt (Recent Filing)$69.93M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding34,324,272
10 Day Avg. Volume103,813
30 Day Avg. Volume119,154
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue5.67
Enterprise Value/Gross Profit7.12
Enterprise Value/Ebitda-49.03
Forecast
1Y Price Target
$20.00Price Target Upside36.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$100.36M
Bulls Say, Bears Say
Bulls Say
RNS Revenue GrowthDouble-digit RNS revenue growth indicates continued adoption of the company’s core therapy and supports a durable expansion trajectory. Sustained growth across the first half, rather than a single quarter, can improve operating leverage and strengthen NeuroPace’s position in drug-resistant epilepsy care.
High Gross MarginGross margins above 80% provide meaningful economic value from each additional RNS System sale and create room to fund sales, research, and clinical development. The upgraded outlook also suggests pricing and manufacturing management are supporting margin durability despite modest cost pressure.
Proprietary AI And Data AssetsA large proprietary intracranial EEG dataset can support differentiated clinical algorithms, personalization, and future workflow tools. Progress in foundational model training and AI-enabled features may deepen physician engagement and expand the strategic value of the installed RNS patient base over time.
Bears Say
High Leverage And Limited Equity CushionThe heavy debt burden relative to equity reduces financial flexibility and leaves less capacity to absorb prolonged losses or fund growth internally. A small equity cushion also increases sensitivity to future capital needs, making execution and progress toward profitability more important for balance-sheet stability.
FDA Uncertainty On IGE ExpansionThe regulatory setback delays potential expansion into a new epilepsy population and creates uncertainty around the timing and requirements for approval. Although NeuroPace has a planned SIR process and amendment path, additional review work could postpone market access and related strategic growth.
Persistent Negative Cash GenerationNegative operating and free cash flow show that NeuroPace has not yet reached self-funding operations, even though cash burn has improved from prior years. Continued investment in commercialization and product development may therefore remain dependent on existing liquidity or external financing.
NeuroPace News
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $9.22 and its highest was $19.60 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $438.32M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.218 by $0.038.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.11.
How many shares outstanding does NeuroPace have?
NeuroPace has 34,324,272 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.218. Following the earnings report the stock price went down -3.256%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (36.24% Upside)
$20.00 (36.24% Upside)
Blogger Sentiment
Neutral
NPCE Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 320.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.79%
12-Months-Change
Fundamentals
Return on Equity
-119.68%
Trailing 12-Months
Asset Growth
-8.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial momentum and improving non‑GAAP profitability metrics, highlighted by double‑digit RNS growth (21%+) and upgraded full‑year guidance and margin outlook. Strategic progress was underscored by the AI product launch (ECoG Assistant), deep proprietary EEG data (27M+ recordings), and ongoing model training and remote care development. The principal negative item was the FDA's determination that the IGE PMA supplement was not approvable in its current form, which introduces regulatory timing uncertainty and the need for additional analyses—however, the agency remained interactive and recommended the SIR process, and management expects to pursue an amendment. Other smaller headwinds included a significant decline in service revenue and modest gross margin pressure. On balance, operational momentum, product innovation, and improved adjusted profitability substantially outweigh the setbacks, though regulatory risk remains a key watch item.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$20.00
▲(36.24% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
16.62% Insiders
9.69% Mutual Funds
41.46% Other Institutional Investors
16.07% Public Companies and
Individual Investors